A mildly decreased glomerular filtration rate, generally meaning an estimated GFR (eGFR) somewhere between 60 and 89 mL/min/1.73 m², often does not signal immediate danger to your kidneys. For many people, especially those over 40, a reading in this range reflects ordinary aging rather than progressive kidney disease. But “mild” is not the same as “meaningless,” and context matters enormously: the same eGFR number can be completely benign in one person and an early warning sign in another, depending on factors like protein in your urine, your cardiovascular health, and whether the number is stable or trending downward over time.
What the Numbers Actually Mean
The international staging system maintained by the Kidney Disease: Improving Global Outcomes (KDIGO) group divides kidney function into categories. An eGFR of 90 or above is considered normal. An eGFR of 60 to 89 falls into the G2 category, labeled “mildly decreased.” Below that, 45 to 59 is G3a (“mildly to moderately decreased”), and the categories continue downward from there. When doctors mention a mildly decreased GFR, they usually mean a G2 reading, though some use the phrase loosely to include the G3a range as well.
A critical point that often gets lost: a single eGFR reading does not, by itself, confirm chronic kidney disease. The KDIGO guidelines require that the abnormality persist for at least three months before a CKD diagnosis applies. A large study of over 117,000 patients in primary care highlighted this distinction, noting that eGFR-based staging from a single creatinine measurement reflects a snapshot classification, not a confirmed chronic condition, because transient dips from dehydration or acute illness cannot be ruled out from one blood draw alone.1PubMed Central. Beyond Numbers: CKD-EPI Versus MDRD in Primary Care—Differences in Chronic Kidney Disease Stage Classification in 117,055 Patients So if you saw a number in the 60-to-89 range on a single lab report, the first step is usually to repeat the test after a few months before drawing conclusions.
Why Your eGFR Might Not Be as Accurate as You Think
Most eGFR values are calculated from a blood test measuring creatinine, a waste product generated by your muscles. The math behind the estimate accounts for your age and sex, but it cannot account for how much muscle you carry. That gap creates real inaccuracies. A study using body-composition scans found that muscle mass consistently skewed eGFR readings: people with more muscle had their kidney function underestimated, while people with very little muscle had theirs overestimated. The error worked out to roughly 6 points of eGFR per 10 kilograms of lean mass.2EClinicalMedicine. How unmeasured muscle mass affects estimated GFR and diagnostic inaccuracy Fat mass, interestingly, did not affect the estimate at all.
This means a muscular person might get an eGFR of 78 when their true kidney function is well above 90. Conversely, someone who has lost substantial muscle from illness or aging could have a reassuringly normal eGFR that hides real kidney impairment. If you are at either extreme of muscularity and your eGFR lands in the mildly decreased range, the number deserves a second look with a different test.
Cystatin C and Getting a Better Answer
That “different test” is usually cystatin C, a small protein produced by nearly all cells in your body at a fairly constant rate. Unlike creatinine, cystatin C levels are not heavily influenced by muscle mass, making it a useful cross-check. Combining creatinine and cystatin C into a single equation improves the accuracy of eGFR estimates, particularly in the range where many people with mildly decreased readings fall.3PubMed Central. Should Cystatin C eGFR Become Routine Clinical Practice?
A large study published in the New England Journal of Medicine demonstrated that cystatin C-based eGFR reclassified a meaningful number of people compared to creatinine alone. In general-population cohorts, the share of people with an eGFR below 60 was about 14% when measured by cystatin C versus about 10% with creatinine. When people were reclassified upward (meaning their kidneys were actually working better than creatinine suggested), their risk of death and cardiovascular events dropped accordingly. When reclassified downward, their risk rose.4PubMed Central. Cystatin C versus creatinine in determining risk based on kidney function In other words, the cystatin C number tracked actual health outcomes more faithfully.
A cross-sectional analysis specifically looked at people in the G2 versus G1 eGFR categories (mildly decreased versus normal by creatinine) and found that adding cystatin C dramatically improved the ability to distinguish between the two groups, with the combined model achieving strong discrimination and significantly improving reclassification accuracy.5Discovery Medicine. Association of Serum Cystatin C With Creatinine-Defined Mildly Reduced eGFR: A Cross-Sectional Analysis of eGFR G2 Versus G1 Categories If your doctor is unsure whether your mildly decreased creatinine-based eGFR reflects real kidney trouble or a measurement artifact, asking about cystatin C testing is reasonable.
Aging and the Slow Drift Downward
Kidney function declines as part of normal aging, and this is one of the main reasons mild decreases in eGFR are so common in older adults. As kidneys age, some filtering units (glomeruli) scar and stop working, while the tissue between them develops fibrosis. Various mechanisms drive this process, and it happens to some degree in virtually everyone.6PubMed Central. Rate of decline in kidney function with age: a systematic review
This creates a genuine dilemma. Research on healthy kidney donors found that the degree of scarring visible on biopsy did not independently predict GFR once age was accounted for. The decline in GFR and the structural changes in the kidney both appear to be universal features of aging rather than evidence that one causes the other in a straightforward way.7PubMed Central. Senile nephrosclerosis–does it explain the decline in glomerular filtration rate with aging? The practical implication: if you are 70 years old and your eGFR is 68 with no protein in your urine and no other risk factors, your kidneys are probably aging on schedule. The number itself may qualify as “mildly decreased” by the staging system, but it does not necessarily mean you have a disease that is going to progress.
What Actually Makes a Mildly Decreased GFR Risky
The single most important factor that separates a harmless mild decrease from an ominous one is albuminuria, the presence of the protein albumin in your urine. A collaborative meta-analysis of high-risk cohorts found that higher albumin-to-creatinine ratio was associated with higher risk of death and cardiovascular death at every level of eGFR, and that lower eGFR increased risk at every level of albuminuria. The two risk factors operate independently and multiply each other’s effects.8Kidney International. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality
A population-based study of adults 75 and older reinforced this finding: albuminuria provided prognostic information beyond what eGFR alone could offer, improving the identification of those at highest risk of death. Macroalbuminuria (a large amount of protein) roughly doubled the mortality risk, independent of eGFR level.9PubMed Central. Implementation of KDIGO CKD Screening and Its Prognostic Implications in Community-Dwelling Adults Aged 75 Years or Older This is why a urine albumin test should accompany any eGFR reading that concerns you. An eGFR of 72 with no albuminuria is a fundamentally different situation from an eGFR of 72 with significant protein leakage.
The Cardiovascular Connection
Mildly decreased kidney function does not exist in isolation from the rest of your body. The kidneys and the heart are closely linked, and data from the Framingham Heart Study showed that even modest eGFR reductions are associated with measurable cardiovascular changes. People with an eGFR of 60 to 69 had roughly 70% higher odds of coronary artery calcification compared to those with an eGFR of 90 or above, after adjusting for traditional risk factors. They also had elevated levels of cardiac stress biomarkers and, over time, a greater risk of cardiovascular disease and CKD progression.10PubMed Central. Association of Mildly Reduced Kidney Function With Cardiovascular Disease: The Framingham Heart Study
A separate study of patients with eGFR values from 45 to 75 found that those at the lower end had more than double the odds of non-fatal heart attack compared with those above 75, after adjusting for age and traditional risk factors.11Nutrition, Metabolism and Cardiovascular Diseases. What Does a Mild Decreased GFR Mean for Kidney Health? The takeaway is not that a mildly decreased GFR means you will have a heart attack. It is that the same metabolic forces (high blood pressure, diabetes, inflammation) that push kidney function down also damage blood vessels, and a dip in eGFR can serve as an early signal that those forces are active.
Factors That Speed Up the Decline
Not everyone with a mildly decreased eGFR will see their numbers continue to drop. A large real-world cohort study identified the factors most strongly linked to rapid eGFR decline in people with early-to-moderate CKD. Diabetes roughly doubled the odds of rapid decline, as did blood pressure at or above 120 systolic, significant anemia, and albuminuria at moderately or severely increased levels. Statin use, on the other hand, was associated with a modest reduction in the odds of rapid progression.12PubMed Central. Predictors of rapid eGFR decline in early to moderate chronic kidney disease (stages G1–G4): insights from a real-world Thai cohort incorporating KDIGO 2024 guidelines
The study also produced a somewhat counterintuitive finding: being in a more advanced CKD stage (G3 or G4) was actually associated with a lower risk of rapid decline compared to those in earlier stages. This may reflect survivorship bias (those who progressed fastest have already moved beyond those stages) or the possibility that some early-stage declines represent an aggressive trajectory that ultimately slows. Either way, an early-stage decline that is moving quickly deserves attention, not dismissal.
Medications deserve mention here too. Nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen are one of the most common kidney stressors. They work by blocking substances that help maintain blood flow to the kidneys, and chronic use is associated with acute kidney injury, inflammation of kidney tissue, and, over time, chronic kidney disease.13PubMed Central. Kidney damage from nonsteroidal anti-inflammatory drugs-Myth or truth? Review of selected literature If your eGFR is already mildly decreased, regular NSAID use is something to discuss with your doctor, particularly if you are also managing high blood pressure or heart conditions.
Hyperfiltration Before the Decline
An eGFR that is abnormally high, rather than low, can actually be the first stage of a problem. Glomerular hyperfiltration occurs when the kidneys work harder than normal, often driven by obesity, early diabetes, or metabolic liver disease. Over time, the overworked filtering units sustain damage, and the eGFR drops. A large health-screening cohort study found that hyperfiltration was a powerful independent risk factor for CKD progression, with those who had hyperfiltration alone facing nearly four times the risk of developing CKD compared to those without it.14PubMed Central. Hepatorenal vulnerability flagged by glomerular hyperfiltration in metabolic liver disease: a large health-screening cohort evidence
This matters for understanding a “mildly decreased” reading because the decline from an abnormally high eGFR to a normal-looking one can mask real damage. Someone whose true baseline eGFR was 130 due to hyperfiltration and has now dropped to 85 has lost substantial function, even though 85 looks fine in isolation. If your history includes obesity, type 2 diabetes, or metabolic syndrome, a mildly decreased eGFR might represent a larger drop than it appears.
How Sex and Age Interact With eGFR Trajectories
The rate at which eGFR declines is not identical between men and women, and the risk factors that accelerate the decline differ by sex. A large population-based cohort study found that up to about age 73, the average rate of eGFR decline was similar in men and women. After 73, men declined faster, particularly men with heart failure (losing about 1.2 mL/min per year versus 0.9 for women) or who smoked (losing about 1.6 per year versus 1.3 for women). Among women over 73, socioeconomic deprivation was one of the most impactful risk factors, whereas cardiometabolic conditions drove the differences in men.15American Journal of Kidney Diseases. Sex Differences in Risk Factors for Decline in Kidney Function: A Population-Based Cohort Study
Another analysis comparing healthy people, those at risk for kidney disease, and those with established CKD found that in healthy and at-risk groups, men actually had lower absolute eGFR values than women of the same age but declined more slowly. However, once CKD was established, the rates of decline between men and women converged.16PubMed Central. Gender differences in age-related decline in glomerular filtration rates in healthy people and chronic kidney disease patients The practical point: men who start with lower baseline numbers may reach the “mildly decreased” threshold earlier in life without it being more dangerous, while the risk factors that matter most for progression differ by sex and age bracket.
Medications That Can Slow Progression
If a mildly decreased eGFR is confirmed to be real and persistent, especially with albuminuria or diabetes present, there are medications that can protect kidney function. SGLT2 inhibitors, originally developed for diabetes, have emerged as a key disease-modifying therapy for CKD. They work by reducing the pressure inside the kidney’s filtering units through a feedback mechanism that operates independently of their blood-sugar-lowering effects.17PubMed Central. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations
When combined with ACE inhibitors (a common blood pressure medication already used to protect the kidneys), SGLT2 inhibitors produce additive benefits: further reduction in blood pressure, suppression of oxidative stress markers, and a physiological profile consistent with lower intraglomerular pressure and reduced cardiorenal risk.18PubMed Central. Renal and Vascular Effects of Combined SGLT2 and Angiotensin-Converting Enzyme Inhibition One thing that sometimes alarms patients: SGLT2 inhibitors typically cause a small initial dip in eGFR during the first few weeks of use. This dip reflects the intended reduction in filtration pressure and is not a sign of harm. It generally stabilizes and is followed by a slower rate of long-term decline compared to not taking the medication.
The evidence for SGLT2 inhibitors is strongest in people with diabetes and CKD, but indications have been expanding to include non-diabetic CKD as well. Whether someone with a mildly decreased eGFR and no other risk factors would benefit from these drugs is less clear. They are not yet standard for that low-risk group, and the decision depends on the full clinical picture.
Dehydration and Other Temporary Dips
Before assuming that a mildly decreased eGFR means anything chronic, consider the circumstances under which the blood was drawn. Dehydration is a surprisingly common cause of transiently abnormal readings. Research on community-dwelling adults found a strong association between markers of dehydration (concentrated urine) and higher eGFR, suggesting the kidneys were hyperfiltrating to compensate. The relationship was J-shaped: mild dehydration pushed eGFR up, but once dehydration became more pronounced, kidney function could swing the other way.19PubMed Central. Sub-morbid dehydration-associated glomerular hyperfiltration: An emerging reality?
Other temporary causes of eGFR dips include recent intense exercise (which releases extra creatinine from muscles), eating a large protein-rich meal before the blood draw, acute illness with fever, and starting certain medications. A single reading of 82 after a hard gym session and a steak dinner is not the same as a consistent reading of 82 across three separate labs drawn under routine conditions. If your first eGFR result concerns you, being well-hydrated, rested, and fasting before the repeat test gives the most reliable comparison.
What to Do With a Mildly Decreased Reading
If you have just received a lab result showing a mildly decreased eGFR, the most useful actions depend on the rest of your clinical picture. For someone with no diabetes, normal blood pressure, no protein in their urine, and no family history of kidney disease, a single reading in the 70s or 80s is usually something to monitor, not to panic about. A repeat test in three to six months, ideally with a urine albumin-to-creatinine ratio, will tell you whether the number is stable.
If albuminuria is present, if you have diabetes or hypertension, or if your eGFR has been trending down over multiple readings, the conversation shifts toward active management. Blood pressure control becomes critical, with targets typically tighter than for the general population. SGLT2 inhibitors and ACE inhibitors or angiotensin receptor blockers form the pharmacological backbone for slowing progression, as described above. Reducing NSAID use, managing blood sugar if diabetic, and addressing cardiovascular risk factors all contribute to protecting the kidneys and the heart simultaneously.
Lifestyle factors play a role as well, though the evidence for specific dietary interventions at the mildly decreased stage is less robust than for more advanced CKD. Moderate sodium restriction, maintaining a healthy weight, staying physically active, and avoiding excessive protein intake are broadly recommended. Animal research has shown that diets high in fat and salt can reduce GFR by a meaningful amount even in the absence of other kidney-damaging conditions,20Physiology. Assessment of Mitochondrial Function in a Mouse Model of Mild Chronic Kidney Disease Induced by High-Fat and High-Salt Diet though translating mouse findings directly to human dietary recommendations requires caution. The underlying principle — that metabolic stress from poor diet adds to the kidney’s workload — is well-accepted even if the precise dietary thresholds for humans are less clear.
Smoking deserves special mention. As noted in the sex-differences data, smoking is one of the strongest accelerators of eGFR decline, particularly in older men. Quitting at any stage provides benefit, and the kidneys, unlike the lungs, do not carry the same degree of irreversible structural damage from past smoking. The filtration rate can stabilize or slow its decline after cessation, especially when other risk factors are also being managed.